Top

Open Access 28-11-2024 | Review Article

Unveiling the Digital Evolution of Molecular Tumor Boards

Authors: Sebastian Lutz, Alicia D’Angelo, Sonja Hammerl, Maximilian Schmutz, Rainer Claus, Nina M. Fischer, Frank Kramer, Zaynab Hammoud

Published in: Targeted Oncology

Abstract

Molecular tumor boards (MTB) are interdisciplinary conferences involving various experts discussing patients with advanced tumors, to derive individualized treatment suggestions based on molecular variants. These discussions involve using heterogeneous internal data, such as patient clinical data, but also external resources such as knowledge databases for annotations and search for relevant clinical studies. This imposes a certain level of complexity that requires huge effort to homogenize the data and use it in a speedy manner to reach the needed treatment. For this purpose, most institutions involving an MTB are heading toward automation and digitalization of the process, hence reducing manual work requiring human intervention and subsequently time in deriving personalized treatment suggestions. The tools are also used to better visualize the patient’s data, which allows a refined overview for the board members. In this paper, we present the results of our thorough literature research about MTBs, their process, the most common knowledge bases, and tools used to support this decision-making process.

Tamborero D, Dienstmann R, Rachid MH, Boekel J, Baird R, Braña I, et al. Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal. Nat Med. 2020;26:992–4. https://doi.org/10.1038/s41591-020-0969-2.CrossRefPubMed

Simon R. Genomic biomarkers in predictive medicine. An interim analysis EMBO Mol Med. 2011;3:429–35. https://doi.org/10.1002/emmm.201100153.CrossRefPubMed

Watson JD. The Human Genome Project: past, present, and future. Science. 1990;248:44–9. https://doi.org/10.1126/science.2181665.CrossRefPubMed

Behjati S, Tarpey PS. What is next generation sequencing? Arch Dis Child - Educ Pract. 2013;98:236–8. https://doi.org/10.1136/archdischild-2013-304340.CrossRef

Kurzrock R, Colevas AD, Olszanski A, Akerley W, Arteaga CL, Carson WE, et al. NCCN Oncology Research Program’s Investigator Steering Committee and NCCN Best Practices Committee Molecular Profiling Surveys. J Natl Compr Canc Netw. 2015;13:1337–46. https://doi.org/10.6004/jnccn.2015.0163.CrossRefPubMed

Halfmann M, Stenzhorn H, Gerjets P, Kohlbacher O, Oestermeier U. User-driven development of a novel molecular tumor board support tool. In: Auer S, Vidal M-E, editors. Data integration in the life sciences. Cham: Springer International Publishing; 2019. p. 195–9.CrossRef

Luchini C, Lawlor RT, Milella M, Scarpa A. Molecular tumor boards in clinical practice. Trends Cancer. 2020;6:738–44. https://doi.org/10.1016/j.trecan.2020.05.008.CrossRefPubMed

Rieke DT, Lamping M, Schuh M, Le Tourneau C, Basté N, Burkard ME, et al. Comparison of treatment recommendations by molecular tumor boards worldwide. JCO Precis Oncol. 2018. https://doi.org/10.1200/PO.18.00098.CrossRefPubMed

Rao S, Pitel B, Wagner AH, Boca SM, McCoy M, King I, et al. Collaborative, multidisciplinary evaluation of cancer variants through virtual molecular tumor boards informs local clinical practices. JCO Clin Cancer Inform. 2020. https://doi.org/10.1200/CCI.19.00169.CrossRefPubMedPubMedCentral

10.

von Bubnoff N Molekulares Tumorboard - DGIM Innere Medizin - eMedpedia. In: springermedizin.de. https://www.springermedizin.de/emedpedia/detail/dgim-innere-medizin/molekulares-tumorboard?epediaDoi=10.1007%2F978-3-642-54676-1_585. Accessed 24 May 2024

11.

(2021) Molekulare Diagnostik und Tumorboards: Kassen und Unikliniken einig über Vergütung. In: AerzteZeitung.de. https://www.aerztezeitung.de/Politik/Molekulare-Diagnostik-und-Tumorboards-Kassen-und-Unikliniken-einig-ueber-Verguetung-419280.html. Accessed 24 May 2024.

12.

Hamamoto R, Koyama T, Kouno N, Yasuda T, Yui S, Sudo K, et al. Introducing AI to the molecular tumor board: one direction toward the establishment of precision medicine using large-scale cancer clinical and biological information. Exp Hematol Oncol. 2022;11:82. https://doi.org/10.1186/s40164-022-00333-7.CrossRefPubMedPubMedCentral

13.

Shirota H, Komine K, Takahashi M, Takahashi S, Miyauchi E, Niizuma H, et al. Clinical decisions by the molecular tumor board on comprehensive genomic profiling tests in Japan: A retrospective observational study. Cancer Med. 2023;12:6170–81. https://doi.org/10.1002/cam4.5349.CrossRefPubMed

14.

Burkard ME, Deming DA, Parsons BM, Kenny PA, Schuh MR, Leal T, et al. Implementation and clinical utility of an integrated academic-community regional molecular tumor board. JCO Precis Oncol. 2017. https://doi.org/10.1200/PO.16.00022.CrossRefPubMedPubMedCentral

15.

Miller RW, Hutchcraft ML, Weiss HL, Wu J, Wang C, Liu J, et al. (2022) Molecular tumor board–assisted care in an advanced cancer population: results of a phase II clinical trial. JCO Precis Oncol e2100524. https://doi.org/10.1200/PO.21.00524

16.

Boerries M (2021) Digitalisierung in der Präzisions-Onkologie | Prof. Dr. Melanie Börries - YouTube. https://www.youtube.com/watch?v=tXXjLkunkOU&feature=youtu.be. Accessed 25 Jul 2024.

17.

Universitätsklinikum Freiburg (2021) Molekulare Präzisionsonkologie im Rahmen des Molekularen Tumorboards Freiburg. https://www.youtube.com/watch?v=NreDbzgG2bI. Accessed 18 Apr 2024.

18.

Hoefflin R, Geißler A-L, Fritsch R, Claus R, Wehrle J, Metzger P, et al. Personalized clinical decision making through implementation of a molecular tumor board: a german single-center experience. JCO Precis Oncol. 2018. https://doi.org/10.1200/PO.18.00105.CrossRefPubMedPubMedCentral

19.

Hoefflin R, Lazarou A, Hess ME, Reiser M, Wehrle J, Metzger P, et al. Transitioning the molecular tumor board from proof of concept to clinical routine: A German single-center analysis. Cancers. 2021;13:1151. https://doi.org/10.3390/cancers13051151.CrossRefPubMedPubMedCentral

20.

Illert L. Molekulare Präzisionsonkologie im Rahmen des Molekularen Tumorboards Freiburg. 2021.

21.

Horak P, Leichsenring J, Goldschmid H, Kreutzfeldt S, Kazdal D, Teleanu V, et al. Assigning evidence to actionability: An introduction to variant interpretation in precision cancer medicine. Genes Chromosomes Cancer. 2022;61:303–13. https://doi.org/10.1002/gcc.22987.CrossRefPubMed

22.

Horak P, Klink B, Heining C, Gröschel S, Hutter B, Fröhlich M, et al. Precision oncology based on omics data: The NCT Heidelberg experience. Int J Cancer. 2017;141:877–86. https://doi.org/10.1002/ijc.30828.CrossRefPubMed

23.

Mock A, Teleanu M-V, Kreutzfeldt S, Heilig CE, Hüllein J, Möhrmann L, et al. NCT/DKFZ MASTER handbook of interpreting whole-genome, transcriptome, and methylome data for precision oncology. NPJ Precis Oncol. 2023;7:1–15. https://doi.org/10.1038/s41698-023-00458-w.CrossRef

24.

Tumorboard - NCT Nationales Centrum für Tumorerkrankungen Heidelberg. https://www.nct-heidelberg.de/fuer-patienten/behandlung/tumorboard.html. Accessed 18 Apr 2024.

25.

Leichsenring J, Horak P, Kreutzfeldt S, Heining C, Christopoulos P, Volckmar A, et al. Variant classification in precision oncology. Int J Cancer. 2019;145:2996–3010. https://doi.org/10.1002/ijc.32358.CrossRefPubMed

26.

Jahn A, Rump A, Widmann TJ, Heining C, Horak P, Hutter B, et al. Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancers. Ann Oncol. 2022;33:1186–99. https://doi.org/10.1016/j.annonc.2022.07.008.CrossRefPubMed

27.

MASTER-Programm jetzt in Videos erklärt - NCT Nationales Centrum für Tumorerkrankungen Heidelberg. https://www.nct-heidelberg.de/fuer-patienten/aktuelles/details/master-programm-jetzt-in-videos-erklaert.html. Accessed 24 May 2024.

28.

NCT/DKTK-MASTER - Krebsgenomanalyse auf dem Weg in die klinische Anwendung. In: NCTDKTK-MASTER. https://www.klinikum.uni-heidelberg.de/newsroom/nctdktk-master/. Accessed 24 May 2024.

29.

MASTER Workflow - NCT Nationales Centrum für Tumorerkrankungen Heidelberg. https://www.nct-heidelberg.de/forschung/molecular-stratification/master/master-workflow.html. Accessed 24 May 2024.

30.

Heining C, Horak P, Gröschel S, Glimm H, Fröhling S. Personalisierte Medizin: Strukturen, Tumorboards, Visionen. Med Genet. 2017;28:452–9. https://doi.org/10.1007/s11825-016-0111-5.CrossRef

31.

Fröhling S. Das MASTER-Programm des Deutschen Krebskonsortiums. 2020.

32.

Molecular Tumor Board. In: UCSF Helen Diller Fam. Compr. Cancer Cent. https://cancer.ucsf.edu/research/molecular-oncology/molecular-tumor-board. Accessed 17 Apr 2024.

33.

UCSF 500 Cancer Gene Panel Test (UCSF500 / UC500). In: UCSF Health Cent. Clin. Genet. Genomics. https://genomics.ucsf.edu/UCSF500. Accessed 24 Apr 2024.

34.

Ciliberto G, Canfora M, Terrenato I, Agnoletto C, Agustoni F, Amoroso L, et al. Bridging therapeutic opportunities: a survey by the Italian molecular tumor board workgroup of Alliance Against Cancer. J Exp Clin Cancer Res. 2022;41:305. https://doi.org/10.1186/s13046-022-02512-0.CrossRefPubMedPubMedCentral

35.

Mateo J, Chakravarty D, Dienstmann R, Jezdic S, Gonzalez-Perez A, Lopez-Bigas N, et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann Oncol. 2018;29:1895–902. https://doi.org/10.1093/annonc/mdy263.CrossRefPubMedPubMedCentral

36.

Malani D, Kumar A, Brück O, Kontro M, Yadav B, Hellesøy M, et al. Implementing a functional precision medicine tumor board for acute myeloid leukemia. Cancer Discov. 2022;12:388–401. https://doi.org/10.1158/2159-8290.CD-21-0410.CrossRefPubMed

37.

Højgaard M, Spanggaard I, Harsløf L, Kringelbach T, Qvortrup C, Yde C, et al. (2022) Danish National Molecular Tumor Board: History, current status, organization and future perspectives

38.

van der Velden DL, van Herpen CML, van Laarhoven HWM, Smit EF, Groen HJM, Willems SM, et al. Molecular Tumor Boards: current practice and future needs. Ann Oncol. 2017;28:3070–5. https://doi.org/10.1093/annonc/mdx528.CrossRefPubMed

39.

Schickhardt C, Horak P, Fröhling S, Winkler EC. Das Molekulare Tumorboard Onkol. 2020;26:431–7. https://doi.org/10.1007/s00761-020-00725-6.CrossRef

40.

Merry D, Schickhardt C, Mehlis K, Winkler EC. Trust and responsibility in molecular tumour boards. Bioethics. 2018;32:464–72. https://doi.org/10.1111/bioe.12464.CrossRefPubMed

41.

Singer J, Irmisch A, Ruscheweyh H-J, Singer F, Toussaint NC, Levesque MP, et al. Bioinformatics for precision oncology. Brief Bioinform. 2019;20:778–88. https://doi.org/10.1093/bib/bbx143.CrossRefPubMed

42.

Rodríguez Ruiz N, Abd Own S, Ekström Smedby K, Eloranta S, Koch S, Wästerlid T, et al. Data-driven support to decision-making in molecular tumour boards for lymphoma: a design science approach. Front Oncol. 2022;12.

43.

Costa PR, Acencio ML, Lemke N. A machine learning approach for genome-wide prediction of morbid and druggable human genes based on systems-level data. BMC Genomics. 2010;11:S9. https://doi.org/10.1186/1471-2164-11-S5-S9.CrossRefPubMedPubMedCentral

44.

Glocker K, Knurr A, Nürnberg S, Al-Hmad J, Czogalla D-I, Izzo M, et al. The Knowledge Connector: Workflow Support for Molecular Tumor Boards.

45.

Jameson JL, Longo DL. Precision medicine — personalized, problematic, and promising. N Engl J Med. 2015;372:2229–34. https://doi.org/10.1056/NEJMsb1503104.CrossRefPubMed

46.

Chakravarty D, Gao J, Phillips S, Kundra R, Zhang H, Wang J, et al. (2017) OncoKB: A precision oncology knowledge base. JCO Precis Oncol 1–16. https://doi.org/10.1200/PO.17.00011

47.

Wagner AH, Walsh B, Mayfield G, Tamborero D, Sonkin D, Krysiak K, et al. A harmonized meta-knowledgebase of clinical interpretations of somatic genomic variants in cancer. Nat Genet. 2020;52:448–57. https://doi.org/10.1038/s41588-020-0603-8.CrossRefPubMedPubMedCentral

48.

Griffith M, Spies NC, Krysiak K, McMichael JF, Coffman AC, Danos AM, et al. CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer. Nat Genet. 2017;49:170–4. https://doi.org/10.1038/ng.3774.CrossRefPubMedPubMedCentral

49.

CIViC - Clinical Interpretation of Variants in Cancer. https://civicdb.org/welcome. Accessed 24 Apr 2024.

50.

Ensembl genome browser 112. https://www.ensembl.org/index.html. Accessed 25 Jul 2024.

51.

Cunningham F, Allen JE, Allen J, Alvarez-Jarreta J, Amode MR, Armean IM, et al. Ensembl 2022. Nucleic Acids Res. 2022;50:D988–95. https://doi.org/10.1093/nar/gkab1049.CrossRefPubMed

52.

Hunt SE, McLaren W, Gil L, Thormann A, Schuilenburg H, Sheppard D, et al. Ensembl variation resources. Database. 2018. https://doi.org/10.1093/database/bay119.CrossRefPubMedPubMedCentral

53.

Joshi-Tope G. Reactome: a knowledgebase of biological pathways. Nucleic Acids Res. 2004;33:D428–32. https://doi.org/10.1093/nar/gki072.CrossRefPubMedCentral

54.

Croft D, Mundo AF, Haw R, Milacic M, Weiser J, Wu G, et al. The Reactome pathway knowledgebase. Nucleic Acids Res. 2014;42:D472–7. https://doi.org/10.1093/nar/gkt1102.CrossRefPubMed

55.

Fabregat A, Korninger F, Viteri G, Sidiropoulos K, Marin-Garcia P, Ping P, et al. Reactome graph database: Efficient access to complex pathway data. PLOS Comput Biol. 2018;14: e1005968. https://doi.org/10.1371/journal.pcbi.1005968.CrossRefPubMedPubMedCentral

56.

Holt ME, Mittendorf KF, LeNoue-Newton M, Jain NM, Anderson I, Lovly CM, et al. (2021) My Cancer Genome: coevolution of precision oncology and a molecular oncology knowledgebase. JCO Clin Cancer Inform 995–1004. https://doi.org/10.1200/CCI.21.00084.

57.

Home - My Cancer Genome. https://www.mycancergenome.org/. Accessed 25 Jul 2024.

58.

Van Allen EM, Wagle N, Stojanov P, Perrin DL, Cibulskis K, Marlow S, et al. Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nat Med. 2014;20:682–8. https://doi.org/10.1038/nm.3559.CrossRefPubMedPubMedCentral

59.

Dienstmann R, Jang IS, Bot B, Friend S, Guinney J. Database of genomic biomarkers for cancer drugs and clinical targetability in solid tumors. Cancer Discov. 2015;5:118–23. https://doi.org/10.1158/2159-8290.CD-14-1118.CrossRefPubMedPubMedCentral

60.

Landrum MJ, Chitipiralla S, Brown GR, Chen C, Gu B, Hart J, et al. ClinVar: improvements to accessing data. Nucleic Acids Res. 2020;48:D835–44. https://doi.org/10.1093/nar/gkz972.CrossRefPubMed

61.

ClinVar. http://www.clinvar.com/. Accessed 25 Jul 2024

62.

BRCA Exchange. https://brcaexchange.org/. Accessed 25 Jul 2024

63.

Cline MS, Liao RG, Parsons MT, Paten B, Alquaddoomi F, Antoniou A, et al. BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2. PLOS Genet. 2018;14: e1007752. https://doi.org/10.1371/journal.pgen.1007752.CrossRefPubMedPubMedCentral

64.

Gudmundsson S, Singer-Berk M, Watts NA, Phu W, Goodrich JK, Solomonson M, et al. Variant interpretation using population databases: Lessons from gnomAD. Hum Mutat. 2022;43:1012–30. https://doi.org/10.1002/humu.24309.CrossRefPubMed

65.

Sherry ST, Ward M-H, Kholodov M, Baker J, Phan L, Smigielski EM, et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 2001;29:308–11. https://doi.org/10.1093/nar/29.1.308.CrossRefPubMedPubMedCentral

66.

MacConaill LE. Existing and emerging technologies for tumor genomic profiling. J Clin Oncol. 2013;31:1815–24. https://doi.org/10.1200/JCO.2012.46.5948.CrossRefPubMedPubMedCentral

67.

Grada A, Weinbrecht K. Next-generation sequencing: methodology and application. J Invest Dermatol. 2013;133:1–4. https://doi.org/10.1038/jid.2013.248.CrossRef

68.

Blasi L, Bordonaro R, Serretta V, Piazza D, Firenze A, Gebbia V. Virtual clinical and precision medicine tumor boards—cloud-based platform–mediated implementation of multidisciplinary reviews among oncology centers in the COVID-19 era: protocol for an observational study. JMIR Res Protoc. 2021;10: e26220. https://doi.org/10.2196/26220.CrossRefPubMedPubMedCentral

69.

NIST Big Data Public Working Group, Definitions and Taxonomies Subgroup. NIST Big Data Interoperability Framework: volume 1, definitions version 3. Gaithersburg: National Institute of Standards and Technology; 2019.

70.

Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6:. https://doi.org/10.1126/scisignal.2004088

71.

Metzger P, Hess ME, Blaumeiser A, Pauli T, Schipperges V, Mertes R, et al. MIRACUM-Pipe: An adaptable pipeline for next-generation sequencing analysis, reporting, and visualization for clinical decision making. Cancers. 2023;15:3456. https://doi.org/10.3390/cancers15133456.CrossRefPubMedPubMedCentral

72.

Glocker K, Knurr A, Al-Hmad J, Czogalla D-I, Izzo M, Koch C, et al. Abstract 848: Taming numerous information on variants for better treatment decisions. Cancer Res. 2020;80:848. https://doi.org/10.1158/1538-7445.AM2020-848.CrossRef

73.

Glocker K, Knurr A, Nürnberger S, Al-Hmad J, Czogalla D-I, Izzo M, et al. (2021) The Knowledge Connector: Workflow Support for Molecular Tumor Boards. German Medical Science GMS Publishing House, p DocAbstr. 392

74.

Yang J, Beißbarth T, Dönitz J, et al. Onkopipe: a snakemake based DNA-sequencing pipeline for clinical variant analysis in precision medicine. In: Röhrig R, Grabe N, Haag M, Hübner U, Sax U, Oliver Schmidt C, et al., editors. Studies in health technology and informatics. IOS Press; 2023.

75.

Schlotzig V, Kornrumpf K, König A, Tucholski T, Hügel J, Overbeck TR, et al. Predicting the effect of variants of unknown significance in molecular tumor boards with the VUS-Predict Pipeline. In: Röhrig R, Beißbarth T, König J, Ose C, Rauch G, Sax U, et al., editors. Studies in health technology and informatics. IOS Press; 2021.

76.

Borchert F, Mock A, Tomczak A, Hügel J, Alkarkoukly S, Knurr A, et al. Knowledge bases and software support for variant interpretation in precision oncology. Brief Bioinform. 2021;22:bbab134. https://doi.org/10.1093/bib/bbab134.CrossRefPubMedPubMedCentral

77.

Perera-Bel J, Hutter B, Heining C, Bleckmann A, Fröhlich M, Fröhling S, et al. From somatic variants towards precision oncology: evidence-driven reporting of treatment options in molecular tumor boards. Genome Med. 2018;10:18. https://doi.org/10.1186/s13073-018-0529-2.CrossRefPubMedPubMedCentral

78.

Kurz NS, Perera-Bel J, lia, H&#246, Ltermann C, Tucholski T, et al. (2022) Identifying actionable variants in cancer—the Dual Web and Batch Processing Tool MTB-Report. In: German Medical Data Sciences 2022 – Future Medicine: More Precise, More Integrative, More Sustainable! IOS Press, pp 73–80

79.

Tamborero D, Dienstmann R, Rachid MH, Boekel J, Lopez-Fernandez A, Jonsson M, et al. The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology. Nat Cancer. 2022;3:251–61. https://doi.org/10.1038/s43018-022-00332-x.CrossRefPubMedPubMedCentral

80.

Li Q, Ren Z, Cao K, Li MM, Wang K, Zhou Y. CancerVar: An artificial intelligence-empowered platform for clinical interpretation of somatic mutations in cancer. Sci Adv. 2022;8:eabj1624. https://doi.org/10.1126/sciadv.abj1624.CrossRefPubMedPubMedCentral

81.

Pagel KA, Kim R, Moad K, Busby B, Zheng L, Tokheim C, et al. Integrated informatics analysis of cancer-related variants. JCO Clin Cancer Inform. 2020. https://doi.org/10.1200/CCI.19.00132.CrossRefPubMedPubMedCentral

82.

Nakken S, Fournous G, Vodák D, Aasheim LB, Myklebost O, Hovig E. Personal Cancer Genome Reporter: variant interpretation report for precision oncology. Bioinformatics. 2018;34:1778–80. https://doi.org/10.1093/bioinformatics/btx817.CrossRefPubMed

83.

Tsimberidou AM, Kahle M, Vo HH, Baysal MA, Johnson A, Meric-Bernstam F. Molecular tumour boards—current and future considerations for precision oncology. Nat Rev Clin Oncol. 2023;20:843–63. https://doi.org/10.1038/s41571-023-00824-4.CrossRefPubMed

84.

Rodon J, Soria J-C, Berger R, Miller WH, Rubin E, Kugel A, et al. Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. Nat Med. 2019;25:751–8. https://doi.org/10.1038/s41591-019-0424-4.CrossRefPubMedPubMedCentral

85.

Le Tourneau C, Kamal M, Trédan O, Delord J-P, Campone M, Goncalves A, et al. Designs and challenges for personalized medicine studies in oncology: focus on the SHIVA trial. Target Oncol. 2012;7:253–65. https://doi.org/10.1007/s11523-012-0237-6.CrossRefPubMed

86.

Tsimberidou AM, Kurzrock R. Precision medicine: lessons learned from the SHIVA trial. Lancet Oncol. 2015;16:e579–80. https://doi.org/10.1016/S1470-2045(15)00397-6.CrossRefPubMed

87.

Larson KL, Huang B, Weiss HL, Hull P, Westgate PM, Miller RW, et al. Clinical outcomes of molecular tumor boards: a systematic review. JCO Precis Oncol. 2021. https://doi.org/10.1200/PO.20.00495.CrossRefPubMedPubMedCentral

88.

Scheiter A, Hierl F, Lüke F, Keil F, Heudobler D, Einhell S, et al. Critical evaluation of molecular tumour board outcomes following 2 years of clinical practice in a Comprehensive Cancer Centre. Br J Cancer. 2023;128:1134–47. https://doi.org/10.1038/s41416-022-02120-x.CrossRefPubMed

89.

Kato S, Kim KH, Lim HJ, Boichard A, Nikanjam M, Weihe E, et al. Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy. Nat Commun. 2020;11:4965. https://doi.org/10.1038/s41467-020-18613-3.CrossRefPubMedPubMedCentral

Title: Unveiling the Digital Evolution of Molecular Tumor Boards
Authors: Sebastian Lutz
Alicia D’Angelo
Sonja Hammerl
Maximilian Schmutz
Rainer Claus
Nina M. Fischer
Frank Kramer
Zaynab Hammoud
Publication date: 28-11-2024
Publisher: Springer International Publishing
Published in: Targeted Oncology
Print ISSN: 1776-2596
Electronic ISSN: 1776-260X
DOI: https://doi.org/10.1007/s11523-024-01109-1

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Targeted Therapy
On-demand webinar

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Keynote series | Spotlight on menopause

Springer Medicine

Unveiling the Digital Evolution of Molecular Tumor Boards

Abstract

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Keynote series | Spotlight on menopause

Springer Medicine

Abstract

Please log in to get access to this content

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma